Annexon, Inc. (ANNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.87+0.62%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ANNX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on progressing pivotal Phase 3 trials for vonaprument and tanruprubart with key data readouts and regulatory submissions expected in 2026.
Stated as a priority in 2 of last 2 quarters. Management emphasized advancing pivotal Phase 3 trials for vonaprument and tanruprubart with key milestones expected in 2026. R&D expenses increased from $35.8M in 2026-Q1 to $46.6M in 2026-Q2, reflecting trial activity. Net loss rose from $44.1M to $55.3M over the same period. The trajectory shows active investment and execution consistent with stated clinical advancement priorities.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“2026 is a defining year for our company, with meaningful progress across both our Guillain-Barré syndrome and geographic atrophy programs.”
“As we execute toward major milestones in 2026, we are sharply focused on our strategic priorities across the organization.”
Ensure sufficient cash and capital resources to fund operations and milestones through late 2027 and extend runway with new credit facility.
Stated in 3 disclosures including 2026-Q1 and Q2 and a 2026-Q3 credit facility announcement. Cash and equivalents declined modestly from $225M in 2026-Q1 to $209.2M in 2026-Q2, while a $200M credit facility was secured in July 2026. Management's statements about runway into late 2027 and 2028 align with these financial resources, indicating delivery on maintaining financial runway.
“Cash, cash equivalents and short-term investments were $209.2 million as of June 30, 2026, expected to fund operations and milestones into 2028.”
“Cash, cash equivalents and short-term investments were $225.0 million as of March 31, 2026, with anticipated runway into second half of 2027.”
Advance tanruprubart through EU Marketing Authorization Application review and prepare Biologics License Application submission with U.S./European data in 2026.
Stated in 2 of last 2 quarters. Management reiterated the EU MAA review and planned BLA submission with U.S./European data from the FORWARD trial expected in 2026. While no revenue or approval milestones are reported yet, the clinical and regulatory progress is consistent with management's stated timeline and focus.
“BLA submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026.”
“MAA under review with EMA supported by robust data package; ongoing FORWARD study to support BLA submission in 2026.”
Complete pivotal Phase 3 trial with dual primary endpoints and prepare for topline data readout in Q4 2026 and final completion in Q3 2027.
Stated in 2 of last 2 quarters. Management confirmed the ARCHER II Phase 3 trial is on track with key data milestones expected in late 2026 and 2027. No revenue yet, but trial progress and timelines align with management's stated clinical development priorities.
“Month 15 primary endpoint on track for fourth quarter of 2026; final trial completion including Month 24 endpoint expected in third quarter of 2027.”
“ARCHER II is ongoing global Phase 3 trial with enrollment completed; topline data expected in fourth quarter of 2026.”
Manage research and development and general administrative expenses to support clinical progress while controlling costs.
Over the trailing year it converted 0.98x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.